These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 32768490)

  • 1. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.
    Bahrampour Juybari K; Pourhanifeh MH; Hosseinzadeh A; Hemati K; Mehrzadi S
    Virus Res; 2020 Oct; 287():198108. PubMed ID: 32768490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
    El-Missiry MA; El-Missiry ZMA; Othman AI
    Eur J Pharmacol; 2020 Sep; 882():173329. PubMed ID: 32615182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
    Sies H; Parnham MJ
    Free Radic Biol Med; 2020 Aug; 156():107-112. PubMed ID: 32598985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147).
    Sehirli AO; Sayiner S; Serakinci N
    Mol Biol Rep; 2020 Oct; 47(10):8229-8233. PubMed ID: 32920757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly?
    Öztürk G; Akbulut KG; Güney Ş
    Turk J Med Sci; 2020 Oct; 50(6):1504-1512. PubMed ID: 32777902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Host Defense System and Rescuing Compromised Mitochondria to Increase Tolerance against Pathogens by Melatonin May Impact Outcome of Deadly Virus Infection Pertinent to COVID-19.
    Tan DX; Hardeland R
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32992875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins in coronavirus outbreak: It's time for experimental and clinical studies.
    Bifulco M; Gazzerro P
    Pharmacol Res; 2020 Jun; 156():104803. PubMed ID: 32289478
    [No Abstract]   [Full Text] [Related]  

  • 9. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
    Banerjee A; Czinn SJ; Reiter RJ; Blanchard TG
    Life Sci; 2020 Aug; 255():117842. PubMed ID: 32454157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microbial coinfection in COVID-19.
    Chen X; Liao B; Cheng L; Peng X; Xu X; Li Y; Hu T; Li J; Zhou X; Ren B
    Appl Microbiol Biotechnol; 2020 Sep; 104(18):7777-7785. PubMed ID: 32780290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the type of diabetes treatment relevant to outcome of COVID-19?
    Bloomgarden Z
    J Diabetes; 2020 Jul; 12(7):486-487. PubMed ID: 32353193
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 update: Covid-19-associated coagulopathy.
    Becker RC
    J Thromb Thrombolysis; 2020 Jul; 50(1):54-67. PubMed ID: 32415579
    [No Abstract]   [Full Text] [Related]  

  • 13. [Not Available].
    Nau JY
    Rev Med Suisse; 2020 Mar; 16(685):510-511. PubMed ID: 32167254
    [No Abstract]   [Full Text] [Related]  

  • 14. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
    Hazra S; Chaudhuri AG; Tiwary BK; Chakrabarti N
    Life Sci; 2020 Sep; 257():118096. PubMed ID: 32679150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 16. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

  • 18. Discovering small-molecule therapeutics against SARS-CoV-2.
    Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
    Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future therapeutical approaches for COVID-19.
    Duan Y; Yao Y; Kumar SA; Zhu HL; Chang J
    Drug Discov Today; 2020 Aug; 25(8):1545-1552. PubMed ID: 32574697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.